Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia


Ciftciler R., DEMİROĞLU H. , HAZNEDAROĞLU İ. C. , SAYINALP N. , AKSU S. , Ozcebe O., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.11, ss.729-734, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Konu: 11
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.clml.2019.08.007
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Sayfa Sayıları: ss.729-734

Özet

Most patients with acute myeloid leukemia (AML) receive intensive induction chemotherapy toward obtaining a complete remission. In this study, we evaluated whether the time from induction chemotherapy to complete remission in patients with AML affects survival outcomes. This study showed that the time between induction chemotherapy and complete remission in patients with AML was effective on survival outcomes. Background: The majority of patients with acute myeloid leukemia (AML) receive intensive induction chemotherapy for obtaining a complete remission (CR). Despite consolidation chemotherapy and advances in allogeneic hematopoietic stem cell transplantation, most of these patients finally relapse and die from AML. The aim of this study is to determine the impact of duration of remission achievement on survival of patients with newly diagnosed AML who achieve CR after induction chemotherapy. Materials and Methods: We retrospectively analyzed patients with AML who received first induction chemotherapy between 2001 and 2018. Results: The 5-year overall survival for patients who had early remission after induction chemotherapy and patients who had delayed remission after induction chemotherapy were 83% (95% confidence interval [CI], 0.79-0.87) and 35% (95% CI, 0.31-0.39), respectively (P <.001). The 5-year disease-free survival for patients who had early remission after induction chemotherapy and patients who had delayed remission after induction chemotherapy were 81% (95% CI, 0.75-0.87) and 28% (95% CI, 0.210.35), respectively (P <.001). Conclusion: In conclusion, time to entering CR is a predictor factor of overall survival and disease-free survival for patients with newly diagnosed AML who achieve CR after first induction chemotherapy. Patients achieving CR only after a lengthy time (eg, more than 29 days) should be considered to have high relapse rate and should undergo allogeneic hematopoietic stem cell transplantation.